PCSK9 inhibition for the treatment of hypercholesterolemia: Promises and emerging challenges
Hypercholesterolemia, is a prominent risk factor for cardiovascular disease (CVD). Undestanding of the biochemical mechanisms that regulate the expression of the low density lipoproteins receptor (LDLR) and the hepatic clearance of LDL cholesterol (LDL-C) paved the way to the statin therapy as the g...
| Main Authors: | , , |
|---|---|
| Format: | Journal Article |
| Published: |
2014
|
| Online Access: | http://hdl.handle.net/20.500.11937/55532 |